Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | USP14 | P54578 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366541 | 0.83 | CCR3 (0.46) | KMT2AMEN1TACR1DRD2POLB | |
| SCHEMBL5369324 | 0.82 | TACR1 (0.38) | TACR1OPRM1OPRL1 | |
| SCHEMBL14417130 | 0.81 | KDR (0.42) | KMT2AMEN1KDRDRD2SSTR1 | |
| SCHEMBL5369342 | 0.81 | SLC6A4 (0.38) | TACR1OPRM1OPRL1 | |
| SCHEMBL5375841 | 0.80 | GAA (0.39) | KMT2AMEN1OPRM1ALDH1A1GRIN2B | |
| SCHEMBL5361858 | 0.80 | CNR1 (0.47) | TACR1 | |
| SCHEMBL5365655 | 0.78 | HSD11B1 (0.51) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL5362767 | 0.73 | MEN1 (0.50) | KMT2AMEN1TACR1OPRM1ALDH1A1 | |
| SCHEMBL11620077 | 0.72 | DRD2 (0.46) | KMT2AMEN1KDRDRD2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11622417 | 0.71 | DRD2 (0.45) | KMT2AMEN1KDRDRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7217823-B2 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217823-B2 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20040142974-A1 | 4,4-disubstituted piperidines, and methods of use thereof | HOEMANN MICHAEL Z (US) | 2004-07-22 | — | — | US | disclosed |
| US-6656953-B2 | Ligands for receptors such as dopamine, serotonin, or norepinephrine transporters; broad uses claimed, such as pain reliever and antidepressant | SEPRACOR INC. | 2003-12-02 | — | — | US | disclosed |
| US-20020177607-A1 | 4,4-Disubstitued piperidines, and methods of use thereof | SEPRACOR INC. | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177607-A1 | 4,4-Disubstitued piperidines, and methods of use thereof | HTR2C, HTR5A, OPRL1 | KMT2A 1835/4885MEN1 2148/4885TACR1 53/4885 |
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | HTR5A, HTR2C, OPRL1 | KMT2A 1721/4885MEN1 1787/4885TACR1 46/4885 |
| US-20040142974-A1 | 4,4-disubstituted piperidines, and methods of use thereof | HTR5A, HTR2C, OPRL1 | KMT2A 1721/4885MEN1 1787/4885TACR1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.